Noninvasive fluorescence excitation spectroscopy for the diagnosis of oral neoplasia in vivo
- PMID: 23085924
- DOI: 10.1117/1.JBO.17.9.097007
Noninvasive fluorescence excitation spectroscopy for the diagnosis of oral neoplasia in vivo
Abstract
Fluorescence excitation spectroscopy (FES) is an emerging approach to cancer detection. The goal of this pilot study is to evaluate the diagnostic potential of FES technique for the detection and characterization of normal and cancerous oral lesions in vivo. Fluorescence excitation (FE) spectra from oral mucosa were recorded in the spectral range of 340 to 600 nm at 635 nm emission using a fiberoptic probe spectrofluorometer to obtain spectra from the buccal mucosa of 30 sites of 15 healthy volunteers and 15 sites of 10 cancerous patients. Significant FE spectral differences were observed between normal and well differentiated squamous cell carcinoma (WDSCC) oral lesions. The FE spectra of healthy volunteers consists of a broad emission band around 440 to 470 nm, whereas in WDSCC lesions, a new primary peak was seen at 410 nm with secondary peaks observed at 505, 540, and 580 nm due to the accumulation of porphyrins in oral lesions. The FE spectral bands of the WDSCC lesions resemble the typical absorption spectra of a porphyrin. Three potential ratios (I410/I505, I410/I540, and I410/I580) were calculated from the FE spectra and used as input variables for a stepwise linear discriminant analysis (SLDA) for normal and WDSCC groups. Leave-one-out (LOO) method of cross-validation was performed to check the reliability on spectral data for tissue characterization. The diagnostic sensitivity and specificity were determined for normal and WDSCC lesions from the scatter plot of the discriminant function scores. It was observed that diagnostic algorithm based on discriminant function scores obtained by SLDA-LOO method was able to distinguish WDSCC from normal lesions with a sensitivity of 100% and specificity of 100%. Results of the pilot study demonstrate that the FE spectral changes due to porphyrin have a good diagnostic potential; therefore, porphyrin can be used as a native tumor marker.
Similar articles
-
Noninvasive diagnosis of oral neoplasia based on fluorescence spectroscopy and native tissue autofluorescence.Arch Otolaryngol Head Neck Surg. 1998 Nov;124(11):1251-8. doi: 10.1001/archotol.124.11.1251. Arch Otolaryngol Head Neck Surg. 1998. PMID: 9821929
-
Discriminant analysis of autofluorescence spectra for classification of oral lesions in vivo.Lasers Surg Med. 2009 Jul;41(5):345-52. doi: 10.1002/lsm.20771. Lasers Surg Med. 2009. PMID: 19533763
-
Native fluorescence spectroscopic characterization of DMBA induced carcinogenesis in mice skin for the early detection of tissue transformation.Analyst. 2015 Jun 21;140(12):4170-81. doi: 10.1039/c4an00650j. Epub 2015 Apr 24. Analyst. 2015. PMID: 25909647
-
Laser-induced autofluorescence spectral ratio reference standard for early discrimination of oral cancer.Cancer. 2008 Apr 1;112(7):1503-12. doi: 10.1002/cncr.23324. Cancer. 2008. PMID: 18260154
-
Role of Salivary Biomarkers in Oral Cancer Detection.Adv Clin Chem. 2018;86:23-70. doi: 10.1016/bs.acc.2018.05.002. Epub 2018 Jul 23. Adv Clin Chem. 2018. PMID: 30144841 Review.
Cited by
-
Optical characterization of normal, benign, and malignant thyroid tissue: a pilot study.J Fluoresc. 2015 Mar;25(2):465-71. doi: 10.1007/s10895-015-1542-0. Epub 2015 Mar 3. J Fluoresc. 2015. PMID: 25731814
-
Future Imaging Alternatives: The Clinical Non-invasive Modalities in Diagnosis of Oral Squamous Cell Carcinoma (OSCC).Open Dent J. 2015 Jul 31;9:311-8. doi: 10.2174/1874210601509010311. eCollection 2015. Open Dent J. 2015. PMID: 26464601 Free PMC article.
-
Monitoring carcinogenesis in a case of oral squamous cell carcinoma using a panel of new metabolic blood biomarkers as liquid biopsies.Oral Maxillofac Surg. 2016 Sep;20(3):295-302. doi: 10.1007/s10006-016-0549-2. Epub 2016 Feb 13. Oral Maxillofac Surg. 2016. PMID: 26875085
-
Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions.Cochrane Database Syst Rev. 2021 Jul 20;7(7):CD010276. doi: 10.1002/14651858.CD010276.pub3. Cochrane Database Syst Rev. 2021. PMID: 34282854 Free PMC article.
-
Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions.Cochrane Database Syst Rev. 2015 May 29;2015(5):CD010276. doi: 10.1002/14651858.CD010276.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2021 Jul 20;7:CD010276. doi: 10.1002/14651858.CD010276.pub3. PMID: 26021841 Free PMC article. Updated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous